About this trial
This clinical trial evaluates the effectiveness of a conversation tool on patient-centered health and decision-making outcomes in patients with lung cancer making treatment decisions. This research is being conducted to help doctors understand the information patients need to participate in shared decision-making about their lung cancer treatment options. The focus of this research is to study how patients choose lung cancer treatment options and the information needed to make that choice, with a focus on patients with lower health literacy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
AIM 1: Suspected lung cancer
AIM 1: English fluency
AIM 1: > 6-month life expectancy
AIM 1: Score of ≥ 3 on the cognitive impairment screener
Disqualifiers
None
Trial design
Parallel
Treatments tested in this trial
Best Practice
Other interventionReceive standard of care
Health Promotion and Education
Other interventionView decision aid
Questionnaire Administration
Other interventionAncillary studies
Treatment groups
Trial outcomes
Primary outcomes
Decision Conflict
Will be assessed using the Decisional Conflict Scale, which contains 16 items. Higher scores indicate higher decisional conflict.
Efficacy of a conversation tool on patients' knowledge of lung cancer
Will be assessed using nine questions from previously validated measures.
Satisfaction with Communication/Confidence in Decision
Will be assessed using the 20-item COMRADE scale. Higher scores indicate better outcomes.
Self-Efficacy
Will be assessed using the Decision Self-Efficacy Scale which contains 11 items. Higher scores indicate higher self-efficacy.
Secondary outcomes
FACT-L
Quality of Life will be assessed by the Functional Assessment of Cancer Therapy -- Lung scale. This scale has 27 items. Higher scores indicate higher quality of life.
Depression/Anxiety
Will be assessed using the 4 item Patient Health Questionnaire for Anxiety and Depression scale. Scores greater than or equal to 3 on the first two questions suggest anxiety, and scores greater than or equal to 3 on the last two questions suggest depression.
Participation in Decision-Making
Will be assessed using the 2-item Control Preferences Scale. Answers of 1 or 2 on both items are categorized as "patient controlled", answers of 3 are categorized as "shared", and answers of 4 or 5 are categorized as "physician-controlled."
Decision Regret
Will be assessed using the 5-item Decision Regret Scale. Higher scores indicate high regret.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
OHSU Knight Cancer Institute
Lead sponsor
Oregon Health and Science University
Collaborator
American Cancer Society, Inc.
Collaborator